INDIANAPOLIS (dpa-AFX) - Eli Lilly and Co. (LLY) Monday announced the presentation of its final survival results of MONARCH 3 clinical trial that evaluated Verzenio at the 2023 San Antonio Breast Cancer Symposium.
At eight years of follow-up, Phase 3, double-blind, placebo-controlled study MONARCH 3 has not shown statistical significance for the overall survival outcome.
Verzenio was studied in combination with an aromatase inhibitor or AI compared to an AI alone as initial endocrine-based therapy for post-menopausal patients with hormone receptor-positive or HR+, human epidermal growth factor receptor 2 negative or HER2- advanced or metastatic breast cancer.
In early breast cancer, an oral presentation will provide results from genomic and transcriptomic profiling analyses of archived primary tumor tissue.
Copyright(c) 2023 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
© 2023 AFX News
